GROW Small Cap Equity Fund Covered Its Position in Harrow (HROW) in Q1
Key takeaways
- In Q1 2026, GROW Small Cap Equity Long/Short L.P (Fund) returned 4.18%, outperforming the Russell 2000 Growth Index’s –2.80%, HFRI Equity Hedge Index’s -0.24%, and the HFRI Fundamental Growth Index’s 0.47% returns.
- In its first-quarter 2026 investor letter, Grow Funds highlighted stocks like Harrow, Inc.
- Grow Funds stated the following regarding Harrow, Inc.
GROW Small Cap Equity Fund Covered Its Position in Harrow (HROW) in Q1 Soumya Eswaran Tue, June 23, 2026 at 7:06 PM GMT+7 2 min read HROW ^RUT Grow Funds, an investment Advisor, released its Q1 2026 investor letter for “GROW Small Cap Equity Long/Short Fund”. A copy of the letter can be downloaded here. In Q1 2026, GROW Small Cap Equity Long/Short L.P (Fund) returned 4.18%, outperforming the Russell 2000 Growth Index’s –2.80%, HFRI Equity Hedge Index’s -0.24%, and the HFRI Fundamental Growth Index’s 0.47% returns. Long positions and hedges, and short positions, safeguarded the portfolio amid the volatility driven by the Iran War. In addition, please check the Strategy’s top five holdings to know its best picks in 2026.
In its first-quarter 2026 investor letter, Grow Funds highlighted stocks like Harrow, Inc. (NASDAQ:HROW). Harrow, Inc. (NASDAQ:HROW) is a US-based pharmaceutical company that focuses on the discovery and development of ophthalmic pharmaceutical products. On June 22, 2026, Harrow, Inc. (NASDAQ:HROW) closed at $42.41 per share. One-month return of Harrow, Inc. (NASDAQ:HROW) was 24.11%, and its shares gained 33.74% over the past 52 weeks. Harrow, Inc. (NASDAQ:HROW) has a market capitalization of $1.58 billion.
Grow Funds stated the following regarding Harrow, Inc. (NASDAQ:HROW) in its Q1 2026 investor letter: